Can peptides cause cancer or accelerate existing cancer?

Cancer initiation and stimulation of an existing tumor are different questions. GH and IGF-1 signaling can support cell growth, making sustained elevation a legitimate concern in people with an existing malignancy. Tesamorelin’s prescribing information contraindicates use with active cancer, calls for careful evaluation after treated cancer, and recommends IGF-1 monitoring. This is a clinically meaningful precaution, not a quantified estimate of cancer risk for every GH peptide.[1]

Human GH data are more nuanced than “growth means cancer.” In the SAGhE cohort, patients treated in childhood for isolated growth failure did not show increased overall cancer risk, although case numbers were limited and patterns differed in higher-risk groups. That evidence concerns medically supervised GH treatment in particular populations. It cannot establish the safety of high exposures, peptide combinations, or years of experimental secretagogue use in healthy adults.[2]

For BPC-157 and other experimental repair peptides, effects on angiogenesis or cell signaling raise questions but do not prove that ordinary human exposure causes cancer. Equally, missing long-term data cannot exclude an effect on an occult tumor. The honest answer is pathway- and product-specific: neither “all peptides cause cancer” nor “they are natural, so cancer is impossible” is supported. A cancer history warrants specialist review before any growth-promoting treatment.[1][3]